Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Developing World Could Be the New IVD Growth Region

By LabMedica International staff writers
Posted on 18 Oct 2011
The next big growth opportunity in in-vitro diagnostics (IVD) is possibly the developing world where high-temperature and scarce water conditions require rapid easy-to-use IVD tests. More...


A new report from Kalorama Information (Rockville Pike, MD, USA) by diagnostic market analyst Shara Rosen and diagnostic consulting network president Brendan O’Farrell describes a quarter-billion dollar market in the next five years for tests that can detect infectious diseases such as malaria and TB—but also rarer diseases like leptospirosis and chikungunya.

The incidence of TB, malaria, hepatitis, and, in particular, HIV/AIDS continues to increase, with HIV/AIDS and TB likely to account for the overwhelming majority of deaths from infectious diseases in developing countries by 2020. Shara Rosen commented, “For the past 10-15 years politicians and aid agencies have come to understand that infectious diseases are not merely causes of suffering and death but also significant barriers to economic development.”

Increased funding for infectious disease diagnostics by groups such as the Bill and Melinda Gates Foundation, the Program for Appropriate Technology in Health (PATH; Seattle, WA, USA) and The Foundation for Innovative New Diagnostics (FIND; Geneva, Switzerland) is helping to develop a new generation of sophisticated test platforms that are designed to meet the needs of low resource environments.

The response of the international community towards the problem has created a market. The report cites a 13% growth rate for sales of point-of-care (POC) tests that treat these most pressing health needs. This is greater than Kalorama forecasts for most areas of the POC diagnostics market.

Shara Rosen added, “There is a huge need for user-friendly, highly specific and reliable technologies for rural and underserved communities worldwide, and that is where the opportunity lies.”

There are at least 75 vendors worldwide that market rapid test kits for emerging infectious diseases. The current market leaders are companies that have invested in sophisticated new technologies and those that have established relationships with governments and international aid agencies.

Kalorama Information supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices, and healthcare; as well as a full range of custom research services.

Related Links:
Kalorama Information
Bill and Melinda Gates Foundation
The Foundation for Innovative New Diagnostics


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automated MALDI-TOF MS System
EXS 3000
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.